GAMBIA-L Archives

The Gambia and Related Issues Mailing List

GAMBIA-L@LISTSERV.ICORS.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
ABDOUKARIM SANNEH <[log in to unmask]>
Reply To:
The Gambia and related-issues mailing list <[log in to unmask]>
Date:
Mon, 4 Jun 2007 11:09:13 +0100
Content-Type:
text/plain
Parts/Attachments:
text/plain (173 lines)
Kabir
  Thanks for the forward. Developing countries are the trial sites for multinational pharmaceutical companies. In mant of these countries there is no ethical rules for scientific research. It is sad the corporate take over is causing hidden genocide in the name of business as usual. They conducted trials on our people and after regulation of the drugs our Governments cannot afford the very drugs.

Kabir Njaay <[log in to unmask]> wrote:
  Nigeria brings criminal charges against Pfizer over 1996 drug test By Robert
Milkowski

4 June 2007

Nigerian government officials last week brought criminal charges against the
Pfizer Pharmaceutical Company for the drug giant's role in the deaths of
children who were treated with an unapproved drug during a meningitis
epidemic.

This is the first time the Nigerian government has taken action concerning
the tragedy. Numerous attempts by the relatives of the victims have been
shot down in US courts. But, more than a decade after this tragic incident,
there is growing public awareness and outcry over the greedy, unethical and
often criminal conduct of multi-national drug companies.

According to a recent *Washington Post* article, "authorities in Kano, the
country's largest state, filed eight charges related to the 1996 clinical
trial, including counts of criminal conspiracy and voluntarily causing
grievous harm. They also filed a civil lawsuit seeking more than $2 billion
in damages and restitution from Pfizer, the world's largest drug company."

In addition to the multinational drug firm itself, the criminal indictment
charges Pfizer's Nigerian subsidiary and eight current or former executives
and researchers. If convicted those named could face up to seven years in
prison.

Aliyu Umar, the Kano attorney general who filed the charges, said that the
prosecution had the backing of the Nigerian government, which provided him
with a six-year-old report concluding that Pfizer's conduct was in violation
of both Nigerian and international law. The Nigerian government said that it
never gave the corporation permission to dispense the untested drug.

"We realize we are the Third World and we need assistance," Umar told the *
Post*. "But we frown on people who think they can take advantage of us,
especially if it's for profit. That's why we decided we needed to take
action against Pfizer. Those people responsible should be punished, whether
in Nigeria or in the United States, for what they did to our people."

A description of the 1996 Nigerian event from the perspective of the
plaintiffs who tried and failed several times over the years to bring civil
charges against Pfizer is harrowing in its detail.

Not long after epidemics of bacterial meningitis, measles and cholera broke
out in Kano, Nigeria, Pfizer established a treatment center at the
Infectious Disease Hospital in Kano to treat meningitis victims. According
to the indictment Pfizer, instead of using safe and effective bacterial
meningitis treatments, seized upon the epidemic as an opportunity to conduct
biomedical research experiments on Nigerian children involving the company's
"new, untested and unproven" antibiotic, Trovan.

Pfizer is charged with failing to explain to the children's parents that the
proposed treatment was experimental, that they could refuse it, or that
other organizations offered more conventional treatments at the same site
free of charge. In addition, plaintiffs assert that half of the children who
participated in Pfizer's treatment program were deliberately given
inadequate doses of ceftriaxone—an FDA-approved drug shown to be effective
in treating meningitis—so that Trovan would look more effective by
comparison. Five of the children who received Trovan and six of the children
who were "low-dosed" with ceftriaxone died and others treated by Pfizer
suffered very serious injuries, including paralysis, deafness and blindness.

One of Pfizer's own researchers, child disease specialist Dr. Juan
Walterspiel, protested in a letter to the company warning that it was
improper to test a drug that had "not been tested for its sensitivity before
the first child was exposed to a live-or-die experiment." He was fired by
the company for speaking out and subsequently won a settlement in a wrongful
dismissal lawsuit.

After the Pfizer test, suspicions ran so high in Kano about the potentially
deadly practices of big drug companies that parents last year refused polio
immunization for their children, fearing the worst. The program was meant to
wipe out the disease in Nigeria, one of its last strongholds.

Pfizer's response to the case was predictable. The company "continues to
emphasize—in the strongest terms—that the 1996 Trovan clinical study was
conducted with the full knowledge of the Nigerian government and in a
responsible and ethical way consistent with the company's abiding commitment
to patient safety. Any allegations in these lawsuits to the contrary are
simply untrue—they weren't valid when they were first raised years ago and
they're not valid today."

But it is indisputable that Pfizer was in Nigeria to test drugs. Their
activities there were driven by the profit motive. If they saved lives, it
was a side result. It would provide them with a touching human interest
story to tell at their next leadership conference in order to enable their
managers to continue to delude themselves that at heart they are really
there to help heal the world—and make a profit! Doctors without Borders, on
the other hand, was set up outside at the same pathetically impoverished
clinic. It was not treating patients with a new, unproven drug and also
dispensing a competitor's drug (in less than adequate doses no less) in
order to do comparisons. They were merely there to try to save lives.

An in-depth *Washington Post* investigative story in December 2000, inspired
in part by the Nigerian tragedy, uncovered the vast use of unregulated
corporate drug experiments in the oppressed countries of Africa and Latin
America as well as in Eastern Europe. It revealed a "poorly regulated
testing system that is dominated by private interests that far too often
betrays its promises to patients and consumers."

"Experiments involving risky drugs proceed with little independent
oversight. Impoverished, poorly educated patients are sometimes tested
without understanding that they are guinea pigs. And pledges of quality
medical care sometimes prove fatally hollow," the* Post* found.

"Drug makers hop borders with scant government review. Largely uninspected
by the Food and Drug Administration—which has limited authority and few
resources to police experiments overseas—US-based drug companies are paying
doctors to test thousands of human subjects in the Third World and Eastern
Europe."

It was the 2000 *Post *article, spelling out the enormity of the problem of
drug companies' avaricious drive to test the potentially next best-selling
drug, that led Aliyu Umar to initiate the legal prosecution in Nigeria. But
it was the corruption of the Nigerian courts that led the children's parents
to pursue their case in the US in 1997. So it is far from certain that there
will be any justice for these impoverished villagers this time around
either.

The political power of the big pharmaceuticals in the US itself has served
to protect their activities. When California's Democratic Representative Tom
Lantos, in response at least in part to the Nigerian case, introduced a bill
called* *"Safe Overseas Human Testing* *Act," which would have supposedly
demanded that companies provide US authorities with details of planned
overseas drug tests and get approval from an ethics committee for the
research, the legislation found only one co-sponsor and quietly died in
committee at the end of the 2006 congressional session.

Public awareness of—and outrage over—the practices of the big pharmaceutical
corporations in the oppressed countries has grow in part as a result of the
success of John le Carré's novel and the 2006 film *The Constant Gardener*.
The popular Cold War spy novelist's fictional account of a young woman who
is murdered when she uncovers crimes committed by a drug company testing a
new tuberculosis vaccine in Kenya is based in large part on the Nigerian
tragedy. In "Criminals of Capitalism," an article he published just before
the release of his novel, le Carré condemned "the conviction that, whatever
profit-driven corporations do in the short term, they are ultimately
motivated by ethical concerns, and their influence on the world is therefore
beneficial, and so God help us all."
In the meantime, Pfizer reported late last year that its third-quarter
earnings had more than doubled from a year earlier. The drug giant's former
CEO, Henry McKinnell, retired last year with a compensation package worth
$200 million. He was the company's executive vice president and chief
financial officer at the time that 11 children died while unwittingly
participating in the Trovan test in Nigeria.


The WSWS invites your
comments.

¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤
To unsubscribe/subscribe or view archives of postings, go to the Gambia-L Web interface
at: http://listserv.icors.org/archives/gambia-l.html

To Search in the Gambia-L archives, go to: http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?S1=gambia-l
To contact the List Management, please send an e-mail to:
[log in to unmask]
¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤


¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤
To unsubscribe/subscribe or view archives of postings, go to the Gambia-L Web interface
at: http://listserv.icors.org/archives/gambia-l.html

To Search in the Gambia-L archives, go to: http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?S1=gambia-l
To contact the List Management, please send an e-mail to:
[log in to unmask]
¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤¤

ATOM RSS1 RSS2